Millennium Management LLC Has $29.73 Million Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Millennium Management LLC raised its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 49.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,145,347 shares of the medical equipment provider's stock after purchasing an additional 377,111 shares during the quarter. Millennium Management LLC owned approximately 2.47% of BioLife Solutions worth $29,733,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. D.A. Davidson & CO. boosted its stake in shares of BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after acquiring an additional 519 shares during the period. 1620 Investment Advisors Inc. boosted its stake in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 675 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after acquiring an additional 950 shares during the period. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of BioLife Solutions by 5.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock worth $532,000 after acquiring an additional 1,047 shares during the period. 93.24% of the stock is currently owned by institutional investors.

Insider Transactions at BioLife Solutions

In other news, insider Sarah Aebersold sold 5,771 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $130,770.86. Following the completion of the transaction, the insider now owns 80,094 shares of the company's stock, valued at approximately $1,814,930.04. The trade was a 6.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 10,589 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $239,946.74. Following the transaction, the executive vice president now directly owns 309,576 shares of the company's stock, valued at $7,014,992.16. This trade represents a 3.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,696 shares of company stock valued at $1,665,094. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Stock Performance

BLFS traded down $0.32 during trading on Friday, hitting $21.78. The stock had a trading volume of 284,704 shares, compared to its average volume of 385,921. The company has a 50 day moving average price of $23.20 and a 200-day moving average price of $25.20. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -20.55 and a beta of 2.01. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $23.94 million during the quarter, compared to analysts' expectations of $22.22 million. As a group, research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BLFS. Wall Street Zen downgraded BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.